PGY-2 Cardiology Residency Program

Purpose of the PGY2 Cardiology Pharmacy Residency Program

The ASHP Accreditation Standard for Postgraduate Year Two (PGY2) Pharmacy Residency Programs (hereinafter the Standard) establishes criteria for systematic training of pharmacists in advanced areas of pharmacy practice. Its contents delineate the requirements for PGY2 residencies, which build upon the foundation provided through completion of an accredited Doctor of Pharmacy degree program and an accredited postgraduate year one (PGY1) pharmacy residency program.

Program Focus and Outcomes

The PGY2 residency in cardiology is designed to transition PGY1 resident graduates from generalist practice to specialized practice that meets the needs of cardiovascular patients.  It is defined as an organized, directed, accredited program that builds upon the competencies of PGY1 pharmacy training.  This residency is focused in cardiovascular pharmacotherapy, clinical research, and academia and is meant to increase the resident’s knowledge, skills, attitudes, and abilities to raise the resident’s level of expertise in medication therapy management and clinical and academic leadership.  

Graduates of the residency program are prepared to assume any of the following roles: 

  • Cardiovascular clinician in both inpatient and outpatient care settings
  • Clinical Educator
  • Clinical Researcher


ASHP Residency Goals and Objectives

The ASHP Competency areas and Goals for this program can be found below:
ASHP Residency Goals and Objectives

Application Requirements

All residents must be eligible for pharmacist licensure in the Commonwealth of Pennsylvania. Applications for Pharmacist License and Intern Registration are available.

Application Process

Eligible candidates will have completed an ASHP accredited PGY1 pharmacy residency program and must submit the standard application requirements via PhORCAS by December 31st. An interview is required.

This residency site agrees that no person at this site will solicit, accept, or use any ranking related information from any residency candidate.

Program Goals
Our residency graduates are prepared to serve as the cardiovascular pharmacotherapy expert as part of a multidisciplinary cardiovascular team. Additionally, they are able to make complex pharmacotherapy recommendations in a dynamic inpatient, outpatient, and telemedicine setting.

Graduates are also experienced in clinical research in the cardiology environment and excel in their ability to teach other health professionals and those in training to be health professionals. They also acquire the experience necessary to exercise leadership for this focus in the health system. A strength of our program and a significant focus is on academic pharmacy practice.

Duration: 12 months
Number Positions: 1
Starting Date: July 1
Salary: $51,037

Benefits: Health, dental, eye care, life, and disability available, Vacation and professional travel provided, Travel stipend available
Training Site Type: Hospital
Owner/Affiliates: Private
Model (type): Teaching, Tertiary
Professional Staff: 48
Total Beds: 1093

Required Learning Experience






2 weeks (early commit)
4 weeks (new resident to institution)



Cardiac ICU (CICU)

1 month



Advanced CICU

1 month




5 weeks


Resident will serve as a primary preceptor for 1 APPE student

Cardiothoracic ICU (CTICU)

1 month



Advanced Heart Failure

1 month



Cardiac Pavilion (General Cardiology)

1 month



Heart Transplantation/Mechanical Circulatory Support

1 month



Clinical Outcomes/Research

1 month



Academic Pharmacy

1 month




2 or 3 months

1 or 2

Depending on orientation






Advanced HF & Pulmonary Hypertension Clinic

5 months

1 and 2


Research Project

12 months

1 and 2


Anticoagulation Committee

12 months

1 and 2



9 months

1 and 2


Code Response

6 months

1 and 2


†Electives may include a learning experience not required (i.e., post-cardiac arrest, electrophysiology, etc.) or can be a repeat of a required experience where the resident demonstrates a specific interest and the experience could be customized to a different focus and/or more advanced level of practice.

    1. Fabrizio C, *Levito MN, Rivosecchi R, Bashline M, Slocum B, Kilic C, et al. Outcomes of systemic anticoagulation with bivalirudin for Impella 5.0. Int J Artif Organs 2021;doi: 10.1177/03913988211032238.

    2. *Levito MN, McGinnis CB, Groetzinger LM, Durkin JB, Elmer J. Impact of benzodiazepines on time to awakening in post cardiac arrest patients. Resuscitation 2021;165:45-49.

    3. Coons JC, Crisamore K, Adams S, Modany A*, Simon MA, Zhao W, et al. A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension. Ther Adv Respir Dis 2021;15:17534666211013688. doi: 10.1177/17534666211013688.

    4. *Colvin BM, Coons JC, Beavers CJ. Guideline-directed heart failure therapy in patients after left ventricular assist device implantation. VAD J 2021;7:Issue 1.

    5. Moreland-Head LN*, Coons JC, Seybert AL, Gray MP, Kane-Gill SL. Use of disproportionality analysis to identify previously unknown drug-associated causes of cardiac arrhythmias using the food and drug administration adverse event reporting system (FAERS) database. J Cardiovasc Pharmacol Ther 2021;26:341-48.

    6. Levito MN*, Coons JC, Verrico MM, Kane-Gill S, Szymkowiak A, Legler B, Dueweke EJ. A system wide approach for navigating interference with unfractionated heparin anti-factor Xa concentrations in the setting of oral factor Xa inhibitor use. Ann Pharmacother 2020; doi: 10.1177/1060028020956271.

    7. Chen HX*, Coons JC, Iasella CJ, Empey PE, Stevenson JM, Kane-Gill SL. Triple antithrombotic therapy with direct oral anticoagulants versus warfarin after percutaneous coronary intervention with genotyping. J Heart Vasc Dis 2019;1(1):Article ID: 100002.

    8. Harris J*, Teuteberg J, Shullo M. Optimal low-density lipoprotein concentration for cardiac allograft vasculopathy prevention. Clin Transplant 2018;32:e13248.

    9. Verlinden NJ*, Coons JC, Iasella C, Kane-Gill SL. Triple antithrombotic therapy with aspirin, P2Y12 inhibitor, and warfarin after percutaneous coronary intervention: an evaluation of prasugrel or ticagrelor versus clopidogrel. J Cardiovasc Pharmacol Ther 2017;22:546-51.

    10. Schwier NC*, Coons JC, Rao SK. Pharmacotherapy update of acute idiopathic pericarditis. Pharmacotherapy 2015;35(1):99-111.

    11. Verlinden NV*, Coons JC. Disopyramide for hypertrophic cardiomyopathy: a pragmatic reappraisal of an old drug.  Pharmacotherapy 2015;35(12):1164-72.

    12. Harris JR*, Coons JC. Ticagrelor use in a patient with a documented clopidogrel hypersensitivity. Ann Pharmacother 2014;48(9):1230-33.

    13. Coons JC, Miller T*. Strategies to reduce bleeding risk in acute coronary syndromes and percutaneous coronary intervention: new and emerging pharmacotherapeutic considerations. Pharmacotherapy 2014;34(9):973-90.

    14. Coons JC, Schwier N*, Harris J*, Seybert AL. Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. Expert Opin Drug Metab Toxicol 2014;10(4):609-20.

    15. Abel EE*, Kane-Gill SL, Seybert AL, Kellum JK. A clinical outcomes comparison between direct thrombin inhibitors for the management of heparin-induced thrombocytopenia in patients receiving renal replacement therapy. Am J Health Syst Pharm 2012;69(18):1559-67.

    16. Gokhman R*, Seybert AL, Phrampus P, Darby J, Kane-Gill SL. Medication errors during medical emergencies in a large, tertiary care, academic medical center. Resuscitation 2012;83(4):482-7.

    17. Devabhakthuni S* and Seybert AL. Oral Antiplatelet Therapy for the Management of Acute Coronary Syndromes: Defining the Role of Prasugrel. Crit Care Nurse 2011;31(1):51-63.

    18. Gokhman R*, Smithburger PL*, Kane-Gill SL, Seybert AL. Pharmacokinetic rationale for combination therapy of pulmonary arterial hypertension. J Cardiovasc Pharmacol 2010;56:686-695.

    19. Zerumsky (Watson) K*, Seybert AL, Saul MI, Lee JS, Kane-Gill SL. Bivalirudin versus unfractionated heparin in percutaneous coronary intervention: determining outcomes and glycoprotein inhibitor use. Pharmacotherapy 2007;27(5):647-656.

    20. Seybert AL, Coons JC, Zerumsky K*. Treatment of heparin-induced thrombocytopenia: Is there a role for bivalirudin? Pharmacotherapy 2006;26(2):229-41.

    21. Coons JC*, Seybert AL, Saul MI, Kirisci L, Kane-Gill SL. Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention. Ann Pharmacother 2005;39(10):1621-6.

2018-19 ACCP National Residency Advisory Committee Appointee – Lindsay Moreland

Grant Total: $5,000. "Clinical Outcomes Comparison of Direct Thrombin Inhibitors for the Management of Heparin-Induced Thrombocytopenia in Patients Receiving Hemodialysis." ASHP Foundation for the New Practitioners Resident Practice-Based Research Grant Program, 2008, Residency Director and Research Mentor

2008 Residency Preceptor of the Year - Amy Seybert
University of Pittsburgh School of Pharmacy

2009 Pharmacy Residency Excellence Preceptor Award - Amy Seybert
ASHP Research and Education Foundation

Program Director

James C. Coons, PharmD, FCCP, FACC, BCCP (Director) 
727 Salk Hall
3501 Terrace Street
Pittsburgh, PA 15261
Phone: 412-648-3088 
FAX: 412-648-8175

UPMC Presbyterian